Novavax says its COVID-19 shot is on track for full FDA approval after delay
WASHINGTON (AP) — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday.
The news sent company shares soaring more than 21% in morning trading and appeared to resolve concerns that Trump administration officials might be holding up a decision on the shot.
Novavax makes the nation's only traditional protein-based COVID-19 vaccine. It is still being sold under emergency use authorization — unlike mRNA vaccines made by Pfizer and Moderna that have earned full FDA approval for certain age groups.
The FDA recently asked Novavax to develop a plan for collecting additional clinical data from those who have gotten the shot, the company said in a statement. It said it is 'engaging with the FDA expeditiously' in hopes of receiving approval 'as soon as possible.'
At FDA, full vaccine approval is the gold standard. The agency was on track to sign off on Novavax's license by its April 1 target date, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss confidential agency matters.
But FDA's acting commissioner, Dr. Sara Brenner, directed the agency's lead official overseeing the vaccine to pause the decision, according to one of the people. The delay, first reported by The Wall Street Journal, sparked concerns of political interference under Robert F. Kennedy Jr., who spent decades leading antivaccine groups before joining the federal government as health secretary.
Last month, FDA's longtime vaccine chief, Dr. Peter Marks, was forced out over disagreements with Kennedy about vaccine safety.
With full FDA approval, Novavax would have permission to keep its shot on the market indefinitely. Products that receive emergency authorization can be removed by FDA after there is no longer a health emergency.
All the COVID-19 vaccines used in the U.S. train the body to fight the coronavirus by recognizing its outer coating, the spike protein.
The Pfizer and Moderna options deliver genetic instructions for the body to temporarily make copies of the protein. In contrast, the Novavax vaccine uses lab-grown copies of the spike protein packaged into nanoparticles and combined with an immune-revving ingredient. Protein-based vaccines have been used for years to prevent other diseases including hepatitis B and shingles.
Each year, the three manufacturers update their vaccine recipes to better match the latest COVID-19 variants that are circulating, just like flu shots are updated yearly.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
24 minutes ago
- The Hill
NIH scientists condemn Trump research cuts
Hundreds of staffers from across the National Institutes of Health (NIH) are speaking out against the politicization of their research and termination of their work while demanding that the drastic changes made at the agency be walked back. In a letter addressed to NIH Director Jay Bhattacharya, more than 2,000 signatories stated, 'we dissent to Administration policies that undermine the NIH mission, waste public resources, and harm the health of Americans and people across the globe.' The letter was titled 'The Bethesda Declaration' in reference to where NIH's campus is located. The signatories cited Bhattacharya's stated commitment to academic freedom that he made in April and called on him to push back against the changes Trump administration has implemented at NIH under his leadership. 'Academic freedom should not be applied selectively based on political ideology. To achieve political aims, NIH has targeted multiple universities with indiscriminate grant terminations, payment freezes for ongoing research, and blanket holds on awards regardless of the quality, progress, or impact of the science,' they wrote. They pointed to U.S. law and prior research that has shown that the participation of diverse populations in studies is necessary for NIH's work. The NIH staffers further blasted the canceling of nearly completed studies. 'Ending a $5 million research study when it is 80% complete does not save $1 million, it wastes $4 million,' they wrote. The researchers called on Bhattacharya to restore foreign collaborations with the global scientific community, put independent peer reviews back in place, bring back terminated NIH staffers and rethink the 15 percent cap on indirect study costs that the Trump administration enacted. 'Combined, these actions have resulted in an unprecedented reduction in NIH spending that does not reflect efficiency but rather a dramatic reduction in life-saving research,' they stated. 'Some may use the false impression that NIH funding is not needed to justify the draconian cuts proposed in the President's Budget. This spending slowdown reflects a failure of your legal duty to use congressionally-appropriated funds for critical NIH research.' NIH research is not solely centered in Bethesda. The agency is responsible for funding research projects across the country and abroad. Numerous lawsuits have been filed to combat the pulling back of billions of dollars in NIH funding. Last week, a federal judge allowed a suit filed by university researchers and public health groups challenging the cuts to move forward. Bhattacharya responded to the letter on the social media platform X. 'We all want @NIH to succeed and I believe that dissent in science is productive. However, the Bethesda Declaration has some fundamental misconceptions about the policy directions NIH has taken in recent months,' he wrote. Bhattacharya said the actions taken at NIH have been to 'remove ideological influence from science' and further argued the agency hasn't halted international scientific collaboration but is instead 'ensuring accountability.' 'Claims that NIH is undermining peer review are misunderstood. We're expanding access to publishing while strengthening transparency, rigor, and reproducibility in NIH-funded research,' he wrote. 'Lastly, we are reviewing each termination case carefully and some individuals have already been reinstated. As NIH priorities evolve, so must our staffing to stay mission-focused and responsibly manage taxpayer dollars.'
Yahoo
38 minutes ago
- Yahoo
Recall issued for potential significant risk with use of Zicam, Orajel swabs. What to know
A "potential microbial contamination" has lead to the recall of several cold nasal swabs and baby teething swabs, according to an announcement from the U.S. Food and Drug Administration June 9. All lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs have been recalled due to the potential contamination. The swabs can "potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections." Here's what you should know. Church & Dwight Co. is recalling all lots of Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs, and Orajel Baby Teething Swabs due to potential microbial contamination identified as fungi in cotton swab components, according to a June 9 news release. The recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by the recall, the news released from the FDA said. As of June 9, "no serious adverse events" associated with the affected product have been reported, the FDA said. Recalled Zicam and Orajel swabs included in the recall are: Zicam Cold Remedy Nasal Swabs, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam Nasal AllClear Swabs, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel Baby Teething Swabs, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. "Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. "The risk is highest — potentially severe or life-threatening — among children and individuals with compromised immune systems or other underlying medical conditions." The recalled products were distributed nationwide in the United States and in Puerto Rico. Consumers who have purchased any of the recalled products should stop using the product immediately, the FDA said. Go to or call the Consumer Relations team at 800-981-4710 for a full refund. This article originally appeared on Treasure Coast Newspapers: Zicam recall: cold nasal swabs. Also Orajel baby teething swabs
Yahoo
an hour ago
- Yahoo
No drug price pledges in talks with US government, Pfizer CEO says
STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
